Literature DB >> 15295369

Two-year infant neurodevelopmental outcome after single or multiple antenatal courses of corticosteroids to prevent complications of prematurity.

Arsenio Spinillo1, Franco Viazzo, Rossella Colleoni, Alberto Chiara, Rosa Maria Cerbo, Elisa Fazzi.   

Abstract

OBJECTIVE: This study was undertaken to evaluate the effect of exposure to multiple antenatal steroid courses on short-term neonatal morbidity and 2-year infant neurodevelopmental outcome. STUDY
DESIGN: This was a prospective observational study of 201 preterm singleton infants who received 1 or more courses of corticosteroids to prevent complications of prematurity and were delivered between 24 and 34 weeks' gestation at a single institution. Neurodevelopmental outcome of the infants was evaluated at 2 years corrected age. Logistic regression analysis was used to perform multivariate analyses of associations and trends.
RESULTS: One hundred thirty-eight subjects (68.7%) received at least 1 complete course of betamethasone, whereas 63 (31.3%) patients were treated with dexamethasone. The prevalence of multiple steroid doses exposure was 26.8% (37/138) in betamethasone and 52.4% (33/63) in dexamethasone group. The prevalence of infant leukomalacia, including both prolonged echogenicity and cystic leukomalacia, was 25.9% (34/131) after a complete corticosteroid course, 40% (6/15) after 1, 42.3% (12/28) after 2, and 44.4% (12/27) after more than 2 additional courses, respectively (adjusted P for trend=.011). In the same categories of steroid exposure, the corresponding prevalences of 2-year infant neurodevelopmental abnormalities were 18% (20/111), 21.4% (3/14), 29.2% (7/24), and 34.8% (8/23), respectively (adjusted P for trend=.038). Multivariate study of first grade interaction suggested that the risk of leukomalacia and 2-year infant neurodevelopmental abnormalities associated with multiple doses exposure was confined to dexamethasone. In fact, compared with betamethasone, exposure to multiple doses of dexamethasone was associated with an increased risk of leukomalacia (19/33 compared with 11/37; odds ratio [OR]=3.21, 95% CI=1.07-9.77) and overall 2-year infant neurodevelopmental abnormalities (12/28 compared with 6/35; OR=3.63, 95% CI=1.03-13.58).
CONCLUSION: In this study, multiple antenatal courses of dexamethasone but not betamethasone were associated with an increased risk of leukomalacia and 2-year infant neurodevelopmental abnormalities.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15295369     DOI: 10.1016/j.ajog.2003.12.023

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  17 in total

1.  The timing of prenatal exposure to maternal cortisol and psychosocial stress is associated with human infant cognitive development.

Authors:  Elysia P Davis; Curt A Sandman
Journal:  Child Dev       Date:  2010 Jan-Feb

2.  Repeated courses of antenatal corticosteroids have adverse effects on aspects of brain development in naturally delivered baboon infants.

Authors:  Amy Shields; Merran Thomson; Vicki Winter; Jacqueline Coalson; Sandra Rees
Journal:  Pediatr Res       Date:  2012-02-14       Impact factor: 3.756

3.  Normal neuropsychological development in children with congenital complete heart block who may or may not be exposed to high-dose dexamethasone in utero.

Authors:  A Brucato; M G Astori; R Cimaz; P Villa; M Li Destri; L Chimini; R Vaccari; M Muscarà; M Motta; A Tincani; F Neri; S Martinelli
Journal:  Ann Rheum Dis       Date:  2006-02-27       Impact factor: 19.103

4.  Neurobehavioral risk is associated with gestational exposure to stress hormones.

Authors:  Curt A Sandman; Elysia Poggi Davis
Journal:  Expert Rev Endocrinol Metab       Date:  2012-07

Review 5.  Steroids and injury to the developing brain: net harm or net benefit?

Authors:  Shadi N Malaeb; Barbara S Stonestreet
Journal:  Clin Perinatol       Date:  2014-03       Impact factor: 3.430

Review 6.  Minireview: the impact of antenatal therapeutic synthetic glucocorticoids on the developing fetal brain.

Authors:  Melanie E Peffer; Janie Y Zhang; Leah Umfrey; Anthony C Rudine; A Paula Monaghan; Donald B DeFranco
Journal:  Mol Endocrinol       Date:  2015-03-12

Review 7.  Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies.

Authors:  Antonio Brucato; Rolando Cimaz; Roberto Caporali; Véronique Ramoni; Jill Buyon
Journal:  Clin Rev Allergy Immunol       Date:  2011-02       Impact factor: 8.667

Review 8.  Effects of antenatal glucocorticoids on the developing brain.

Authors:  Ross Carson; A Paula Monaghan-Nichols; Donald B DeFranco; Anthony C Rudine
Journal:  Steroids       Date:  2016-06-23       Impact factor: 2.668

9.  The effects of antenatal corticosteroids and surfactant replacement on neonatal respiratory distress syndrome.

Authors:  Suada Heljić; Hajrija Maksić; Ismeta Kalkan; Belma Krdalić
Journal:  Bosn J Basic Med Sci       Date:  2009-08       Impact factor: 3.363

10.  Antenatal dexamethasone treatment leads to changes in gene expression in a murine late placenta.

Authors:  B Baisden; S Sonne; R M Joshi; V Ganapathy; P S Shekhawat
Journal:  Placenta       Date:  2007-06-07       Impact factor: 3.481

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.